- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2016 (HIV treatment) and 2019 (PrEP).
- Why 4/10
- Descovy is already approved and commercialized with no pending PDUFA, pivotal readout, or label-expansion decision in the next 12 months. Per the impact score rubric, an approved marketed drug with no imminent new regulatory decision scores 3-5. Descovy is a significant revenue contributor but is one of many products in Gilead's diversified portfolio, so the score is set at 4.
Descovy has no upcoming binary catalyst of its own; it is a mature cash-flow product within Gilead's broader HIV franchise. The next major Gilead catalyst is the anito-cel PDUFA date on December 23, 2026, which is unrelated to Descovy. Watch for quarterly sales trends, particularly any cannibalization from Gilead's own Yeztugo (lenacapavir) and the impact of generic Truvada competition on PrEP pricing.
Price Chart
Executive Summary
Descovy (emtricitabine/tenofovir alafenamide) is an already-approved, marketed HIV drug from Gilead Sciences. First approved by the FDA in April 2016 for HIV-1 treatment and expanded in October 2019 for HIV pre-exposure prophylaxis (PrEP), it is a mature commercial product with no pending regulatory catalyst. In Q3 2026, Descovy generated $1.0 billion in sales (+49% year-over-year), driven by higher average realized price and favorable inventory dynamics, with PrEP accounting for roughly 80% of total sales. The drug faces growing internal competition from Gilead's own twice-yearly injectable PrEP Yeztugo (lenacapavir), as well as external competition from generic Truvada and Apretude. Patent protection is complex, with some primary patents expired and secondary patents potentially extending exclusivity into the 2030s.
How It Works
Descovy is a combination of two antiviral drugs (emtricitabine and tenofovir alafenamide) that block HIV from replicating. It is taken as a daily oral tablet. For HIV treatment, it is used alongside other antiretroviral drugs. For PrEP (pre-exposure prophylaxis), it is taken by HIV-negative individuals to prevent infection if exposed to the virus.
Trial Status
Descovy was first FDA-approved in April 2016 for HIV-1 treatment in combination with other antiretrovirals, and received a second approval in October 2019 for HIV PrEP. The label was expanded in 2025 to include pediatric patients weighing at least 14 kg. It is a fully commercialized, marketed product with no ongoing pivotal trials for new indications.
The Two-Sided Case
Upcoming Catalysts
- No upcoming regulatory catalyst specific to Descovy; it is a mature marketed product.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GILEAD SCIENCES, INC. 8-K GILD ·Originating report